Virta Health
$1.1Bpaper valuation
// OVERVIEW
Virta Health is a chronic disease reversal company that convinced investors to pay $1.1 billion for a nutrition coaching business — call it diabetes management if it helps with the pitch deck. The company sells continuous remote care for Type 2 diabetes and pre-diabetes through employer health plans, positioning metabolic intervention as clinical infrastructure rather than weight loss coaching with medical supervision.
// HQ
San Francisco, United States
// STATUS
PRIVATE
// FOUNDED
2014
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
chronic care
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
The platform combines continuous glucose monitoring devices, ketogenic diet protocols, and remote physician oversight through a mobile app. Patients receive real-time glucose data, medication adjustment, and health coaching designed to reduce HbA1c levels and eliminate insulin dependence. The technology stack is telemedicine infrastructure applied to metabolic disease — sensors feeding data to doctors who adjust prescriptions and nutritionists who adjust meal plans.
// WOWLS ASSESSMENT
Virta operates in the permanent overlap between weight loss, diabetes care, and preventive medicine — a $300 billion US market where behavior change is the product and patient adherence is the perpetual problem. The business model depends on employer health plans paying $370 per member per month for a service that requires sustained dietary compliance from populations who have already demonstrated they will not sustain dietary compliance. Competitors include Omada Health at $635M valuation, Dario Health, and the entire incumbent diabetes care industry that generates revenue from chronic disease persistence not reversal. GLP-1 drugs — Ozempic, Wegovy, Mounjaro — achieved what ten years of diabetes coaching apps could not: actual weight loss and glycemic control in non-compliant patients, prescribed by doctors who trust pharmaceuticals more than nutrition protocols. Virta's clinical outcomes depend on patients adhering to restrictive ketogenic diets indefinitely; semaglutide requires a weekly injection and produces better results.
// WHY WOWLS HUNTS THIS
Because employer health plans will pay for outcomes not intentions, and the pharmaceutical industry just delivered better diabetes reversal through chemistry than the coaching industry delivered through compliance.
// VALUATION NOTE
Valuation is from 2021 Series E. Post-GLP-1 emergence no recent price discovery.
VERDICT: HUNTED — GLP-1 PRESCRIPTIONS IN THE US HIT 9 MILLION IN 2024 AND VIRTA'S ENTIRE VALUE PROPOSITION DEPENDS ON PATIENTS PREFERRING PERMANENT CARBOHYDRATE RESTRICTION TO A WEEKLY INJECTION
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Virta Health.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Virta Health?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN